StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN)

StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a report published on Thursday. The brokerage issued a sell rating on the stock.

Oragenics Stock Performance

Shares of OGEN opened at $0.26 on Thursday. The business’s fifty day moving average price is $0.29 and its two-hundred day moving average price is $0.35. The firm has a market capitalization of $3.12 million, a price-to-earnings ratio of -0.04 and a beta of 0.85. Oragenics has a 52 week low of $0.24 and a 52 week high of $3.43.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.